197 related articles for article (PubMed ID: 35570229)
1. Long-term chemoprevention in patients with adenomatous polyposis coli: an observational study.
Neuhann TM; Haub K; Steinke-Lange V; Morak M; Laner A; Locher M; Holinski-Feder E
Fam Cancer; 2022 Oct; 21(4):463-472. PubMed ID: 35570229
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of carcinogenesis in familial tumors.
Ishikawa H
Int J Clin Oncol; 2004 Aug; 9(4):299-303. PubMed ID: 15375706
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
8. [Chemoprevention of familial cancer].
Ishikawa H
Gan To Kagaku Ryoho; 1997 Jun; 24(8):951-7. PubMed ID: 9212803
[TBL] [Abstract][Full Text] [Related]
9. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
10. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of familial adenomatous polyposis.
Lynch PM
Fam Cancer; 2016 Jul; 15(3):467-75. PubMed ID: 27083160
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
Tonelli F; Valanzano R; Messerini L; Ficari F
J Surg Oncol; 2000 May; 74(1):15-20. PubMed ID: 10861602
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with sulindac of adenomatous polyps in familial polyposis].
Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
16. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
18. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Asano TK; McLeod RS
Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
[TBL] [Abstract][Full Text] [Related]
19. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
20. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]